addS

Wednesday, 29 July 2015

Menomune (Meningococcal Vaccines) - Forecast and Market Analysis to 2022

Meningococcal disease is an acute infection caused by the gram-negative bacterium Neisseria meningitidis. Its rapid onset and severity of symptoms makes prompt and effective diagnosis and treatment nearly impossible. For these reasons the meningococcal disease space is dominated by vaccines.

To Browse a Full Report with TOC: http://www.researchmoz.us/menomune-meningococcal-vaccines-forecast-and-market-analysis-to-2022-report.html

Menomune (Meningococcal Polysaccharide Vaccine, Groups A, C, Y, and W-135 Combined) is the brand name for Sanofi’s tetravalent polysaccharide vaccine sold in the US and Australia to protect against four N. meningitidis serogroups that cause meningococcal disease. Approved in the US in 1981 and Australia in 1994, Menomune was among the first available vaccines against meningococcal disease and was the standard of care in the US until the introduction of Menactra in 2005.

Scope

Overview of Meningococcal disease, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

Detailed information on Menomune including product description, safety and efficacy profiles as well as a SWOT analysis.

Sales forecast for Menomune for the top nine countries from 2012 to 2022.

Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan, Australia and Brazil.

Reasons to buy

Understand and capitalize by identifying products that are most likely to ensure a robust return

Stay ahead of the competition by understanding the changing competitive landscape for meningococcal vaccines

Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential

Make more informed business decisions from insightful and in-depth analysis of Menomune performance

Obtain sales forecast for Menomune from 2012-2022 in top nine countries (the US, France, Germany, Italy, Spain, the UK, Japan, Brazil and China)

Table of Contents

1 Table of Contents 5

1.1 List of Tables 7

1.2 List of Figures 7

2 Introduction 8

2.1 Catalyst 8

2.2 Related Reports 9

2.3 Upcoming Related Reports 10

3 Disease Overview 11

3.1 Etiology and Pathophysiology 11

3.1.1 Etiology 11

3.1.2 Pathophysiology 13

3.2 Symptoms 14

3.3 Prognosis 15

4 Disease Management 16

4.1 Meningococcal Immunization Policy 17

To Download Sample Report With TOC: http://www.researchmoz.us/enquiry.php?type=sample&repid=171854

About ResearchMoz

ResearchMoz is the world’s fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz’s service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.

Contact Us:

Mr. Nachiket

State Tower,

90 State Street,

Suite 700,

Albany NY - 12207

United States

Email: sales@researchmoz.us

Blog: http://dynamicmarketresearch.blogspot.com/

Tel: 866-997-4948 (Us-Canada Toll Free)

Tel: +1-518-621-2074

No comments:

Post a Comment